Planor is intended to address the symptoms associated with chronic inflammatory disorders. Its primary uses include the management of rheumatoid arthritis (RA) and certain types of psoriatic arthritis. The medication is also utilized to manage manifestations of severe, active Crohn's disease, particularly when initial therapies have proven insufficient. The goal of this therapy is to reduce key signs of inflammation, such as persistent pain, swelling, and morning stiffness in affected joints, as well as providing symptomatic control for bowel discomfort in specific scenarios.

---

The clinical strategy seeks to support overall quality of life and functional ability for patients with these chronic illnesses.

“Supporting patients' ability to manage daily activities is a primary benefit of this treatment approach.”

---

Quick Fact: Relief for Joint Stiffness

---

Planor is a therapeutic option for these conditions. For more detailed information, consult with a healthcare professional.

Planor is approved for use only in adults age 18 years and older. Its use is defined by strict population eligibility rules outlined in official regulatory documents. The criteria determine which patient groups are permitted, restricted, or prohibited from initiating treatment.

Population Eligibility Status	Defining Condition or Population
Contraindicated (Must not use)	Known hypersensitivity to Innodil; Active, serious infections, including active tuberculosis; Severe hepatic impairment (Child-Pugh Class C); Pregnancy.
Restricted/Not Recommended	Children and adolescents under 18 years; Severe renal impairment; Moderate hepatic impairment; Breastfeeding.

Official labeling dictates that Planor is prohibited for patients who are pregnant, and safety and efficacy have not been established for use in the pediatric population. Use is restricted in cases of severe kidney impairment, necessitating specific regulatory consideration. The medicine is not recommended for women who are breastfeeding or for patients with moderate liver disease. Older adults (age 65+) may use Planor, but require regulatory assessment of their renal function prior to starting treatment. These conditions establish a clear framework of exclusions and conditional use defined by regulatory authorities.

Planor (mefenamic acid) is a Nonsteroidal Anti-inflammatory Drug (NSAID) and can interact with numerous other medications, potentially altering their effects or increasing the risk of adverse events. It is essential to inform your healthcare provider of all prescription drugs, over-the-counter medicines, and supplements you are taking.

Major Interactions

Co-administering Planor with certain medication classes requires close monitoring or should generally be avoided due to the risk of serious complications, particularly bleeding or renal damage.

Drug Class	Potential Outcome	Monitoring/Action
Anticoagulants/Antiplatelets (e.g., Warfarin, low-dose Aspirin)	Increased risk of serious bleeding and gastrointestinal harm.	Monitor for signs of bleeding, prothrombin time (INR) checks. Avoid co-administration when possible.
Other NSAIDs/Salicylates	Increased risk of serious gastrointestinal side effects.	Avoid concurrent use of Planor with other NSAIDs (like ibuprofen, naproxen).
Corticosteroids (e.g., Prednisone)	Increased risk of gastrointestinal ulceration or bleeding.	Use with caution, monitor for GI symptoms.

Other Significant Interactions

Planor may interfere with the efficacy or toxicity of other drugs, often affecting blood pressure or kidney function:

• ACE Inhibitors/ARBs/Diuretics: Concomitant use may reduce the blood pressure-lowering effect and increase the risk of kidney problems, especially in elderly or dehydrated patients.
• Lithium: Planor can increase the serum concentration of Lithium, leading to potential toxicity. Levels must be monitored closely.
• Selective Serotonin Reuptake Inhibitors (SSRIs): Increased risk of bleeding.
• Methotrexate: Planor can increase Methotrexate levels, enhancing its toxicity.

Food and Product Interactions

While food does not typically affect mefenamic acid absorption significantly, taking the medication with food or milk may help reduce gastrointestinal upset. Certain antacids, particularly those containing magnesium hydroxide, may increase the absorption and concentration of Planor in the body, which could increase the risk of side effects. Alcohol consumption, especially when regular or heavy, significantly increases the risk of serious stomach bleeding when combined with Planor.

How Planor Works

The mechanism of action for Planor's active ingredient, Innodil, is rooted in its role as a Dopamine Receptor Modulator, focusing entirely on modulating activity within the central nervous system's key pathways.

---

Modulation of Dopamine D2 Receptor Signaling

Innodil acts via partial agonism at the Dopamine D2 Receptors (D2R), generating a sub-maximal intrinsic activity at the receptor site. This targeted interaction initiates an inhibitory signaling sequence coupled to the D2R that partially suppresses the Adenylyl Cyclase enzyme, thereby regulating the intracellular concentration of the second messenger, cAMP. This action results in the modulation of signal intensity, reducing the response in hyperdopaminergic conditions and providing activity in hypodopaminergic conditions.

---

Influence on Motor Command Execution Circuits

The modulation of the D2R occurs within pathways essential for motor command execution, notably the Nigrostriatal Pathway. The resulting regulated activity limits the amplitude of neuronal firing rate variations, influencing the operational state of the Basal Ganglia circuits. This signal output is the primary physiological consequence stemming from Innodil's modulation of dopamine receptor signaling.

The administration of Planor follows established protocols to ensure predictable usage in the management of chronic conditions. The medicine is available as an oral tablet and must be administered exclusively via the oral route.

Administration Scope

Field	Instruction Statement
Route of administration	Oral (by mouth).
Dosing schedule	There is a defined maintenance dose range and a maximum daily dose for each approved indication.
Timing in relation to meals (if applicable)	Instructions detailing the required timing relative to food intake (e.g., with or without a meal) are provided in the product guidelines.
Age-group administration rules	Explicit dose adjustments are required for older adults and for patients with documented hepatic or renal impairment.
Special procedural conditions	The tablet must be swallowed whole with liquid and must not be crushed or broken, unless explicitly authorized.

---

Instruction Classifications (High-level)

The established dosing is intended for a once-daily schedule to promote adherence over extended periods. Planor is authorized for use as part of a long-term management plan, which confirms its role in sustained, chronic support rather than for short-term or acute episodes. The entire protocol is structured around consistent, long-term use that sustains the desired physiological state.

Research evidence / Overview of Studies for Planor

This overview summarizes the research that describes the use of Planor (Innodil) in its main indications. The information reflects what types of studies were conducted, what outcomes were measured, and where evidence gaps remain, based solely on authoritative sources.

---

Evidence Supporting Use in Rheumatoid Arthritis (RA)

Research exploring the use of Planor in rheumatoid arthritis primarily relies on Randomized Controlled Trials (RCTs). These short-term studies, often lasting 12 to 24 weeks, were conducted in adult patients with moderate to severe active RA. The trials included groups receiving the medicine and groups receiving either a placebo or an active standard therapy for comparison. This approach allows researchers to characterize the patterns observed during the study period.

What Researchers Studied and Reported

Researchers utilized specific composite scores to measure changes in disease activity and inflammatory signs. Outcomes related to physical discomfort and systemic or functional imbalance were evaluated. Studies also tracked physical function using validated scales, and the long-term observational studies monitored changes in structural joint integrity using X-ray scoring systems. Findings reported in these studies described patterns in the measured outcomes that were observed between the active treatment groups and the control groups. For instance, studies reported how symptoms evolved in the observed populations.

What Remains Uncertain

While findings describe patterns related to short-term changes in symptoms and function, the available evidence provides limited information on the long-term measurements when compared against some other existing advanced therapies. The follow-up durations were limited in the pivotal RCTs. Data for certain subgroups, such as patients with extremely severe or refractory disease, remain insufficient and require further research.

Evidence Supporting Use in Psoriatic Arthritis (PsA)

The research for psoriatic arthritis was also evaluated in Randomized Controlled Trials, often involving placebo controls. These studies explored how Planor was evaluated in the context of the fluctuating or episodic manifestations of PsA in adult patients, including those who had an inadequate measure of change to prior conventional treatments.

What Researchers Studied and Reported

Studies monitored outcomes related to both peripheral joint swelling and tenderness as well as skin involvement, using separate scoring systems for each domain. Researchers also specifically examined outcomes linked to inflammatory states, such as the whole-digit swelling known as dactylitis and inflammation where tendons attach to bone (enthesitis). Reported outcomes from the trials described patterns of change in the measurements for these joint and skin features that were observed across the active treatment groups and the placebo groups at the primary endpoint. Studies also monitored the change in structural joint integrity via radiographic assessments over periods extending up to one year.

What Remains Uncertain

Results apply primarily to the populations studied. However, data for certain groups remain insufficient, specifically those whose disease primarily involves the axial skeleton (spine), compared to those with peripheral joint disease. Findings reported across studies described some variability in the magnitude of observed change in different clinical features, such as skin symptoms versus joint symptoms. The studied populations may not fully represent all PsA patients.

Evidence Supporting Use in Crohn's Disease (CD)

For Crohn's disease, the evidence relies on large-scale Phase III Randomized Controlled Trials structured with a short induction phase followed by a longer maintenance phase. These studies were conducted in adult patients with moderately to severely active CD, often including patients who had not responded adequately to or were intolerant of prior therapies.

What Researchers Studied and Reported

Research examined the achievement of clinical response and clinical remission status, which reflects the presence of fewer symptoms and inflammatory outcomes capturing phases of heightened symptom activity. Studies utilized standardized scoring systems and patient-reported outcomes describing perceived discomfort. Researchers also monitored objective healing of the intestinal lining using endoscopic assessments. Trials reported a pattern where measurements of clinical remission status were observed for a greater proportion of patients in the active treatment groups compared to control groups during both the short-term induction and long-term maintenance phases.

What Remains Uncertain

The available data regarding the maintenance of remission beyond 52 weeks primarily stems from non-randomized, open-label extension studies, meaning the long-term randomized evidence is limited. Furthermore, comparative evidence is lacking against some other advanced therapies. Subgroup findings remain uncertain for specific complications of CD, such as perianal or fistulizing disease, compared to luminal inflammation.

Long-Term Data and Follow-Up Studies

The pivotal short-term RCTs that established the initial use of Planor typically ran for 12 to 24 weeks, or up to 52 weeks for the maintenance phase in Crohn's disease. Beyond these defined intervals, data related to the sustained tracking of outcomes are gathered primarily through long-term observational extension studies where patient cohorts are monitored over several years. These research scenarios help explore how outcomes related to systemic or functional imbalance evolve over extended periods. While these studies monitor long-term outcomes, they are not typically blinded or randomized, meaning the evidence quality varies across studies when interpreting measurements of sustained change over many years.

Evidence in Specific Patient Groups

The majority of controlled research was conducted in adult patients with moderate to severe disease activity, including those who had experienced an inadequate measure of change to prior treatments. Research has explored outcomes in these difficult-to-treat cohorts, providing context for the observed patterns. However, specific, dedicated research describing patterns in children, older adults, or in patients with certain comorbid conditions remains less defined. Consequently, data for certain groups remain insufficient, and study results apply primarily to the adult populations with active disease that were included in the pivotal trials.

What is Still Uncertain in the Research Record

A key limitation across the research for Planor is that long-term effects are not fully established by strictly randomized data beyond one to two years, as most extended follow-up occurs in open-label settings. Findings were mixed or less defined for certain specific clinical manifestations within the approved indications, such as axial involvement in PsA or perianal disease in Crohn's. Research describes group patterns, but study results reflect the specific conditions under which they were conducted and do not provide individual predictions. This reflects the reality that research is ongoing, and certainty remains low for some aspects of long-term data.

Key Studies & References ACR/EULAR Guideline for the Management of Rheumatoid Arthritis—Summary of Evidence Review

Common questions about Planor (FAQ)

Q: What is the timeframe for Planor to start feeling effective?

A: Planor is often prescribed for the short-term relief of pain or for specific chronic conditions, where the full benefit may be observed over the course of the treatment period. Official information indicates that the time it takes for the therapeutic effect to start can vary depending on the condition being treated and the individual patient response.

Q: Does Planor have a generic version available, and what is its name?

A: Yes, Planor contains the active ingredient Innodil (Mefenamic Acid). According to regulatory records, generic formulations containing Mefenamic Acid are available for use in the same approved conditions.

Q: Is it normal to experience a headache when first starting Planor?

A: Headache and dizziness are listed among the commonly reported side effects of this medicine in official product information. If a headache becomes bothersome, persistent, or severe, patients are generally advised to discuss it with their prescribing healthcare provider.

Q: What should I do if I miss a dose of Planor?

A: Official patient information often instructs that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is generally skipped, and the regular schedule is resumed. Regulatory advice also cautions against taking a double dose to make up for a missed one.

Q: Can Planor be taken with food, or does it need to be taken on an empty stomach?

A: Official labeling suggests taking the medicine with food, milk, or an antacid. This is a recommended strategy to help reduce the potential for gastrointestinal upset or irritation, which is a known risk with this class of medication.

Q: Can Planor cause drowsiness or affect my ability to drive?

A: Dizziness or drowsiness are reported as possible side effects of this medicine. Because these are possible effects, caution is typically advised before engaging in activities requiring full mental alertness, such as driving or operating heavy machinery.

Q: Will Planor interfere with the effectiveness of birth control pills?

A: Planor has been observed to interact with certain oral contraceptives, which can potentially increase the risk of high potassium levels in the blood. Patients taking oral contraceptives are generally advised to consult their healthcare provider about this combination to discuss potential effects and necessary monitoring.

Q: Can I take herbal supplements or vitamins while on Planor?

A: It is required in official guidelines to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and supplements you are currently taking. This is necessary because some supplements may carry a risk of interacting with Planor or altering its effects.

Q: Does Planor interact with blood pressure medications?

A: Yes, regulatory documents indicate that Planor may reduce the effectiveness of certain blood pressure-lowering medications, such as ACE Inhibitors, ARBs, and diuretics. It can also cause an increase in blood pressure itself, requiring close monitoring.

Q: What organ systems, like the liver or kidneys, are affected by Planor?

A: Official warnings highlight potential serious adverse effects on the kidneys and the liver. These risks can include issues like renal papillary necrosis or hepatotoxicity, especially when the medicine is used for extended periods. Monitoring may be necessary for patients with pre-existing conditions.

Q: Is it safe to take Planor if I have a pre-existing heart condition?

A: Planor carries a warning about an increased risk of serious cardiovascular events, including heart attack and stroke. This risk is particularly relevant for patients with pre-existing heart disease. The medicine is contraindicated (must not be used) in patients who have recently undergone coronary artery bypass graft (CABG) surgery.

Q: What should I look out for as a sign that Planor is working?

A: The medicine is prescribed for symptomatic relief in its approved conditions. Signs that the treatment may be working typically involve a measurable reduction in symptoms such as pain, inflammation, swelling, and tenderness, based on the assessments of a healthcare professional.

Q: Is it possible for Planor to cause weight gain or weight loss?

A: Official safety information notes that Planor is commonly associated with fluid retention and oedema (swelling). This fluid retention can sometimes lead to a noticeable weight increase. Weight loss is not typically reported as an expected side effect.

Q: Does Planor affect sleep patterns (e.g., insomnia or excessive sleepiness)?

A: Nervousness or trouble sleeping (insomnia) are listed in the official drug information as possible, though less common, side effects. If sleep patterns are severely affected, patients are typically advised to consult with their healthcare provider.

Q: Does Planor affect mental clarity or concentration?

A: As Planor can cause side effects like dizziness and nervousness, changes in concentration or a feeling of confusion may be experienced. If these symptoms are significant or persistent, reporting them to a healthcare professional is generally recommended.

Q: Does Planor affect my ability to get a sunburn?

A: Official regulatory documents and product information for Planor do not typically list photosensitivity (increased sensitivity to sunlight) as a known or common side effect. Patients may wish to continue standard sun safety precautions.

Q: Can Planor be used for pain relief other than its primary indication?

A: In addition to its use in specific chronic inflammatory conditions, the medicine is officially indicated for the relief of mild to moderate pain and for the treatment of primary dysmenorrhea (menstrual cramps). Its use is limited to these approved indications.

Q: Is it normal for Planor to cause dry mouth or dizziness?

A: Dizziness is commonly listed in the official safety profile. Although dry mouth is a known potential side effect of some medications, patients are generally advised to report any new or bothersome symptoms to their healthcare provider.

Q: Can Planor affect my mood or cause unusual behavioral changes?

A: Nervousness is listed as a possible side effect in drug information. If you experience significant, unusual changes in mood or any unexpected behavioral changes, patients are advised to seek medical attention promptly.

Q: Does Planor affect blood sugar levels?

A: Planor may increase the risk of low blood sugar (hypoglycemia) when it is used at the same time as certain diabetes medications, such as insulin or oral hypoglycemics. Patients with diabetes may need to monitor their blood sugar levels more frequently when starting this medicine, as determined by their physician.

Q: What is the connection between Planor and the CYP450 enzymes in the liver?

A: Planor is processed, or metabolized, in the liver primarily by a group of enzymes known as CYP450. Understanding this metabolic pathway is important because it explains how Planor can interact with other medicines that are processed by the same enzymes, potentially changing their concentration in the body.

Q: Does Planor affect fertility in men or women?

A: Official regulatory information states that Planor may impair female fertility. Discontinuation of the medicine may be considered by a healthcare professional for women who are trying to conceive or undergoing fertility investigations.

Q: Is it necessary to have regular blood tests while taking Planor?

A: Monitoring may be necessary for patients with certain risk factors, such as those with existing kidney or liver impairment, or those taking interacting medications like Warfarin or Lithium. Official product information also recommends regular blood pressure monitoring.

Q: Is it common to feel restless or hyperactive when first starting Planor?

A: Nervousness is a reported side effect of the medicine. Any feelings of restlessness or hyperactivity may be discussed with a healthcare provider, especially if they are new or concerning.

Q: Does Planor need to be tapered off, or can it be stopped abruptly?

A: Planor is not typically associated with physical dependence and withdrawal symptoms that require a long tapering process. However, all changes to treatment, including discontinuation, are typically recommended to be discussed with a healthcare provider.

Q: Are the side effects of Planor permanent or do they go away after stopping the drug?

A: Most side effects are generally reversible and tend to resolve upon discontinuation of the medicine. However, the regulatory label notes that serious effects, such as cardiovascular or significant kidney damage, are risks associated with the medicine and can potentially be irreversible.

Q: Can Planor cause changes in vision or eye issues?

A: Visual disturbances are listed among the rare or less common adverse effects in the official safety profile. If changes in vision occur, patients are generally instructed to seek prompt consultation from a healthcare provider.

Q: Is there a specific time of day that Planor should be taken?

A: The medicine is often prescribed for a once-daily schedule to help patients take it consistently. While consistency is important, the specific time of day is generally less critical than ensuring it is taken consistently and with food to minimize the risk of stomach upset.

Q: How long does Planor usually stay in your system after the last dose?

A: The half-life of Planor in the body is documented in official pharmacokinetic properties as being approximately 2 to 4 hours. This measure indicates the time it takes for the concentration of the drug in the body to decrease by half.

Q: How does Planor interact with grapefruit juice?

A: Grapefruit juice is known to interfere with the metabolism of certain medications, which can lead to increased drug levels in the bloodstream. While the official label may not explicitly list grapefruit juice for Planor, it is generally recommended to discuss all significant food and product intake with a healthcare professional.

Q: What are the typical benefits I can expect from Planor treatment?

A: The medicine is intended to provide symptomatic relief and improve physical function in patients with its approved conditions. According to pharmacodynamic studies, expected benefits include a reduction in pain, inflammation, and other specific disease-related symptoms. Individual patient response to treatment can vary.

How to Store and Dispose of Planor: Official Regulatory Information

The following requirements are based strictly on mandatory governmental regulatory labeling for pharmaceutical products.

Mandatory Storage Conditions

Planor must be stored at a controlled room temperature, typically between 20 C and 25 C. It is explicitly prohibited to allow the medicine to freeze.

Protection and Stability

Keep Planor in its original, tightly closed container to ensure Packaging Integrity and maintain Product Stability. The medicine must be protected from both excessive light and moisture. If the container is opened or the product is reconstituted, follow the label instructions to discard any unused portion after the specified in-use period.

Handling and Disposal

For Child Safety, always store Planor out of the sight and reach of children. The official Disposal Pathway requires that expired or unused medicine be taken to an approved pharmaceutical collection point. Do not dispose of Planor via household trash, down a drain, or into the toilet, as this may violate environmental regulations.